CVRx, Inc. announced the appointment of Robert John as Chief Revenue Officer effective June 27, 2024. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. John brings over 25 years of sales leadership experience in the medical device industry, with a strong track record of building high-performing sales teams. Most recently, he served as Divisional Vice President and General Manager of Cardiac Rhythm Management EMEA at Abbott, where he led a global business unit spanning over 90 countries.

Prior to this role, he was first Senior Vice President, then the Divisional Vice President of the Heart Failure business, responsible for integrating the Thoratec and CardioMEMs businesses and leading the commercial teams for St. Jude, then at Abbott post-acquisition. Prior to the acquisition, John held multiple commercial leadership positions at St.

Jude Medical across the Cardiac Rhythm, Electrophysiology, Capital, Structural Heart, Vascular and Heart Failure businesses. Prior to Abbott/St. Jude, John held commercial roles at Medtronic, Guidant and Pfizer.

He holds a Bachelor of Science from the University of North Texas and a Master of Arts in Human Resources Management from the University of Alabama, Tuscaloosa.